Clinical trial
A Study of Imatinib and Docetaxel in Prostate Cancer
NCT00251225 · Leonard Appleman, Other · Completed
Key facts
| NCT number | NCT00251225 |
|---|---|
| Title | A Study of Imatinib and Docetaxel in Prostate Cancer |
| Official title | A Phase II Study of Imatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer |
| Lead sponsor | Leonard Appleman, Other |
| Collaborators | Novartis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Gleevec, Docetaxel |
| Enrollment | 49 |
| Start date | Aug 1, 2005 |
| Primary completion | Mar 1, 2009 |
| Completion | Mar 1, 2014 |
| First posted | Nov 9, 2005 |
| Last update posted | Aug 9, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: